Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (DE:ISI)
FRANKFURT:ISI
RESEARCH TOOLSreports
Ionis Pharmaceuticals (ISI) Stock Price & Analysis
0 Followers
ISI Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€31.29 - €49.00
Previous Close€38.92
Volume0.00
Average Volume (3M)172.00
Market Cap
€5.70B
Enterprise Value€3.74B
Total Cash (Recent Filing)$2.33B
Total Debt (Recent Filing)$257.04M
Price to Earnings (P/E)N/A
Beta0.03
Next Earnings
May 01, 2024EPS Estimate
-€0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding145,751,797
10 Day Avg. Volume3
30 Day Avg. Volume172
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)15.66
Price to Sales (P/S)7.24
Price to Cash Flow (P/CF)46.10
P/FCF Ratio31.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.28
Enterprise Value/Gross Profit4.81
Enterprise Value/Ebitda-12.24
Forecast
1Y Price Target
€55.22Price Target Upside41.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Ionis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesPositive results from clinical trials, including the Phase III BALANCE study in FCS, bolster Ionis's market position with potential for reductions in triglycerides.
Market Position & Product LaunchIonis is ahead of the competition in developing treatments for FCS and sHTG, with multiple products expected to launch, moving the company towards cash-flow positivity.
Stock UpgradeAnalyst upgrades Ionis to Outperform based on underappreciated revenue potential in SHTG and a promising catalyst path.
Bears Say
Clinical Trial ConcernsInvestor confidence in TTR silencers was eroded after ALNY modified its HELIOS-B trial design.
Financial PerformanceSpinraza revenue was below analyst and consensus estimates.
Market CompetitionThe hereditary angioedema prophylactic market is increasingly competitive and fragmented, which could limit upside potential for Ionis's revenue forecasts.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
ISI FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was €31.29 and its highest was €49.00 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Currently, no data Available
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is May 01, 2024 which is in 6 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Feb 21, 2024. The company reported -€0.057 earnings per share for the quarter, beating the consensus estimate of -€0.757 by €0.701.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -€0.93.
How many shares outstanding does Ionis Pharmaceuticals have?
Currently, no data Available
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -€0.057 in its last earnings report, beating expectations of -€0.757. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Among the largest hedge funds holding Ionis Pharmaceuticals’s share is Tweedy Browne CO LLC. It holds Ionis Pharmaceuticals’s shares valued at 175M.
---
Ionis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€55.22 (41.88% Upside)
€55.22 (41.88% Upside)
Blogger Sentiment
Bullish
DE:ISI Sentiment 71%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.27%
12-Months-Change
Fundamentals
Return on Equity
-76.29%
Trailing 12-Months
Asset Growth
18.00%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
---
ISI Company Deck
---
ISI Earnings Call
Q4 2024
0:00 / 0:00
---
ISI Revenue Breakdown
60.82% R&D
39.18% Commercial
---
ISI Stock 12 Months Forecast
Average Price Target
€55.22
▲(41.88% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Illumina
―
Arrowhead Pharmaceuticals
―
Alnylam Pharma
―
Sarepta Therapeutics
―
Best Analysts Covering ISI
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+16.49%
initiated a buy rating 7 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +16.49% per trade.
---